Funding
← Back to your selection

Safar Partners

Activity from announced rounds

Activity in this selectionBiotech
Rounds participated in
2
Confirmed lead rounds
0
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$148M
2 disclosed · full round size, not this investor’s share

By stage

Seed1
Series B1

By primary sector

Biotech2

By country

United States2

Rounds

2 in this selection
Soufflé Therapeutics

Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.

$135MSeries B
Participant
GelMEDIX

Develops regenerative therapies to restore vision by regenerating damaged retinal cells

$13MSeed
Role not disclosed